Chemical Linkers in Antibody-Drug Conjugates (ADCs)
BUY a copy for only $175 or get it FREE with an order of $1,500 or MORE!
One book per customer upon request. PLEASE NOTE: Book is shipped separately from products ordered. Please allow 7-10 days for delivery.
*This promotion is only applicable to customers within the United States.
Chemical Linkers in Antibody-Drug Conjugates (ADCs), Edited by Floris L. van Delft and John M. Lambert.
The covalent conjugation of monoclonal antibodies (mAbs) and cytotoxic drugs, known as antibody-drug conjugates (ADCs), is rapidly becoming a powerful component of cancer treatment. Hundreds of thousands of research articles and reviews are readily accessible on the World Wide Web, reporting and discussing ADCs in varying levels of detail. However, while much attention has been paid to the antibodies and the cytotoxic agents, less attention has been paid until recently to the chemical linkers that connect the targeting mAb with the toxic payload. However, a growing body of evidence suggests that an ADC’s linker is as important as the mAb and the cytotoxin the mAb carries.